Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo

Brain Research

Volumn 722, Issue 1-2, 1996, Pages 12-18

  Dajas Bailador, Federico ^a   Costa, Gustavo ^a   Emmett, Stevan ^b   Bonilla, Carolina ^a   Dajas, Federico ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

acetylcholine; acetylcholinesterase; acetylcholinesterase inhibitor; dopamine; fasciculin; microdialysis; physos tigmine; push pull perfusion; striatum

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; FASCICULIN 2; PHYSOSTIGMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION;

EID: 0029904327     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00133-3     Document Type: Article

References (41)

1. Anderson, A.J., Harvey, A.L. and Mbugua, P.M., Effects of fasciculin 2, an anticholinesterase polypeptide from green mamba venom, on neuromuscular transmission in mouse diaphragm preparations, Neurosci. Lett., 54 (1985) 123-128.
2. Augustinsson, K., Eriksson H., and Faijersson Y., A new approach to determining cholinesterase activities in samples of whole blood, Clin. Chim. Acta, 89 (1978) 239-252.
3. Bartholini, G. and Stadler, H., Cholinergic and gabaergic influence on the dopamine release in extrapyramidal centers. In O. Almgren, A. Carlsson and J. Engel (Eds.), Chemical Tools in Catecholamine Research, Vol. II, 1975, pp. 235-241.
4. Bartholini, G., Stadler, H., Gadea Ciria, M. and Lloyd, K.G., The use of the push-pull cannula to estimate the dynamics of acetylcholine and catecholamines within various brain areas. Neuropharmacology, 15 (1976) 515-519.
5. Bartholini, G., Functional neuronal relations in the basal ganglia and their clinical relevance. In M. Sandler, C. Feuerstein and B. Scatton (Eds.), Neurotransmitter Interactions in the Basal Ganglia, Raven Press, New York, 1987, pp. 1-5.
6. Becker, R.E. and Giacobini, E., Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: can acetylcholine levels in the brain be improved in Alzheimer's disease? Drug Devel. Res., 14 (1988) 235-246.
7. Bolioli, B., Castelló, M., Jerusalinsky, D., Rubinstein, M., Medina, J. and Dajas, F., Neurochemical and behavioral correlates of unilateral striatal acetylcholinesterase inhibition by fasciculin in rats, Brain Res., 504 (1989) 1-6.
8. Bourdois, P.S., Mitchell, J.F., Somogyi, G.T. and Szerb, J.C., The output per stimulus of acetylcholine from cerebral cortical slices in the presence or absence of cholinesterase inhibition, Br. J. Pharmacol., 52(1974) 509-517.
9. Castelló, M., Bolioli, B., Silveira, R. and Dajas, F., Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats, Pharmacol. Biochem. Behav., 41 (1992) 547-550.
10. Clarke, P.B.S., Reuben, M. and El-Bizri, H., Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum, Br. J. Pharmacol., 111 (1994) 695-702.
11. Dajas, F., Bolioli, B., Castelló, M. and Silveira, R., Rat striatal acetylcholinesterase inhibition by fasciculin (a polypeptide from green mamba snake venom), Neurosci. Lett., 77 (1987) 87-91.
12. Dajas, F., Silveira, R. and Cerveñansky, C., Fasciculin: neuropharmacology of potent anticholinesterase polypeptide, Meth. Neurosci., 8 (1992) 258-270.
13. Damsma, G., Westerink, B.H.C., de Vries, J.B. and Horn, A.S., The effect of systemically applied cholinergic drugs on the striatal release of dopamine and its metabolites, as determined by automated brain dialysis in conscious rats, Neurosci. Lett., 89 (1988) 349-354.
14. de Boer, P., Westerink, B.H.C. and Horn, A.S., The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses, Neurosci. Lett., 116 (1990) 357-360.
15. Di Chiaria, G., Morelli, M. and Consolo, S., Modulatory functions of neurotransmitters in the striatum: ACh/Dopamine/NMDA interactions, Trends Neurol. Sci., 17 (1994) 228-233.
16. Fossier, P., Baux, G. and Tauc, L., Fascilulin II, a protein inhibitor of acetylcholinesterase, tested on central synapses of Aplysia, Cell. Mol. Neurobiol., 6 (1986) 221-225.
17. Giorguieff, M.F., Le Floc'h, M.L., Glowinski, J. and Besson, M.J., Involvement of cholinergic presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of dopamine from striatal dopaminergic terminals in the rat, J. Pharmacol. Exp. Ther., 200 (1977) 535-544.
18. Grenhoff, J. and Svensson, T.H., Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine, Arch. Pharmacol., 346 (1992) 395-398.
19. James, M.K. and Cubeddu, L.X., Frequency-dependent muscarinic receptor modulation of acetylcholine and dopamine release from rabbit striatum, J. Pharmacol. Exp. Ther., 229 (1984) 98-104.
20. Karlsson, E., Mbugua, P. and Rodriguez-Ithurralde, D., Fasciculins, anticholinesterase toxins from the venom of the green mamba Dendroaspis angusticeps, J. Physiol., 79 (1984) 232-240.
21. Liu, J.K. and Kato, T., Effect of physostigmine on relative acetylcholine output induced by systemic treatment with scopolamine in in vivo microdialysis of rat frontal cortex, Neurochem. Int., 24 (1994) 589-596.
22. Messamore, E., Ogane, N. and Giacobini, E., Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum, Neuropharmacology, 32 (1993) 291-296.
23. Nilsson, O.G., Kalén, P., Rosengren, E. and Björklund, A., Acetylcholine release in the rat hippocampus as studied by microdialysis is dependent on axonal impulse flow and increases during behavioural activation, Neuroscience, 36 (1990) 325-338.
24. Paxinos, G. and Watson, G., The Rat Brain in Sterotaxic Coordinates, 2nd. edn., Academic Press, Australia, 1986.
25. Pereira, E.F.R., Alkondon, M., Reinhardt, S., Maelicke, A., Peng, X., Lindstrom, J., Whiting, P. and Albuquerque, E.X., Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells, J. Pharmacol. Exp. Ther., 270 (1994) 768-778.
26. Plotkin, D.A. and Jarvik, L.F., Cholinergic dysfunction in Alzheimer disease: cause or effect? In J.M. van Ree and S. Matthysse (Eds.), Psychiatric Disorders: Neurotransmitters and Neuropeptides, Progress in Brain Research Vol. 65, Elsevier, Amsterdam, 1986, pp. 91-103.
27. Quinn, D.M., Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states, Chem. Rev., 87 (1987) 955-979.
28. Radic, Z., Durán, R., Vellón, D.C., Li, Y., Cerveñansky, C. and Taylor, P., Site of fasciculin interaction with acetylcholinesterase, J. Biol. Chem., 269 (1994) 11233-11239.
29. Raiteri, M., Marchi, M. and Maura, G., Presynaptic muscarinic receptors increase striatal dopamine release evoked by "quasi-physiological" depolarization. Eur. J. Pharmacol., 83 (1982) 127-129.
30. Rapier, C., Lunt, G.G. and Wonnacott, S., Steroselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. J. Neurochem., 50 (1988) 1123-1130.
31. Rapier, C., Lunt, G.G. and Wonnacott, S., Nicotinic modulation of 3H dopamine release from striatal synaptosomes: pharmacological characterisation, J. Neurochem., 54 (1990) 937-945.
32. Sakurai, Y., Takano, Y., Kohjimoto, Y., Honda, K. and Kamiya, H., Enhancement of 3H dopamine release and its 3H metabolites in rat striatum by nicotinic drugs, Brain Res., 242 (1982) 99-106.
33. 3H-dopamine in the striatum: an adaptation of the push-pull cannula method to awake restrained and anesthetized rats, Brain Res. Bull., 16 (1986) 149-154.
34. Shaw, K.P., Aracava, Y., Akaike, A., Daly, J.W., Rickett, D.L. and Albuquerque, E.X., The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex, Mol. Pharmacol., 28 (1985) 527-538.
35. Summers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K. and Kling, A., Oral tetrahydroaminoacridine in long-term treatment of senile dementia. Alzheimer type, N. Eng. J. Med., 315 (1986) 1241-1287.
36. Tavitian, B., Pappata, S., Planas, A.M., Jobert, A., Bonnot-Lours, S., Crouzel, C. and Di Giamberardino, L., In vivo visualization of acetylcholinesterase with positron emission tomography, Neuroreport, 4 (1993) 535-538.
37. Trabucchi, M., Cheney, D.L., Hanin, I. and Costa, E., Application of principles of steady-state kinetics to the estimation of brain acetylcholine turnover rate: effects of oxotremorine and physostigmine, J. Pharmacol. Exp. Ther., 194 (1975) 57-64.
38. Ungerstedt, U. and Hallström, Å., In vivo microdialysis - a new approach to the analysis of neurotransmitters in the brain, Life Sci., 41 (1987) 861-864.
39. Westernick, B.H.C., de Boer, P. and Damsma, G., Dopamine-acetylcholine interaction in the striatum studied by microdialysis in the awake rat: some methodological aspects, J. Neurosci. Methods, 34 (1990) 117-124.
40. Williams, M., Sullivan, J.P. and Arneric, S.P., Neuronal nicotinic acetylcholine receptors, D.N. and P., 7 (1994) 205-223.
41. Xiao, W.B., Nordberg, A. and Zhang, X., Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the Extracellular concentration of acetylcholine in the striatum of anesthetized rats, J. Pharmacol. Exp. Ther., 265 (1993) 759-764.